BeiGene (ONC) Soars 3.2%: Is Further Upside Left in the Stock?

Company Overview - BeiGene, Ltd. (ONC) shares increased by 3.2% to $244.20 in the last trading session, with a notable trading volume, and have gained 6.5% over the past four weeks [1][2] Sales Growth Potential - The stock price rally is driven by positive investor sentiment regarding the sales growth potential of its oncology products, including Brukinsa (zanubrutinib) and Tevimbra (tislelizumab), along with several other pipeline candidates for various cancer treatments [2] Financial Expectations - The company is projected to report a quarterly loss of$ 0.80 per share, reflecting a year-over-year increase of 77.3%, with expected revenues of $1.09 billion, up 71.5% from the same quarter last year [3] - The consensus EPS estimate for the quarter has been revised 12.8% higher in the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [4] Industry Context - BeiGene is part of the Zacks Medical - Biomedical and Genetics industry, where Applied Therapeutics Inc. (APLT) has a Zacks Rank of 3 (Hold) and has seen a decline of 8.5% in the past month [4][5]